San Francisco startup Structure Therapeutics is usually focusing on an oral, once-day by day GLP-1 drug identified as GSBR-1290—the drug surpassed Wall Street’s expectations in June whenever a mid-stage review showed regular weight loss of about 6% and it ideas to start another mid-p